Review



fc fgfr1 chimeric protein  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    R&D Systems fc fgfr1 chimeric protein
    Avastin enhances VEGF binding to heparin and heparin binds VEGF–Avastin complexes and enhances VEGF binding to Avastin. A, streptavidin-coated 96-well microtiter plates were coated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml) and incubated with 125I-VEGF (10 ng/ml) alone or with Avastin at the concentrations indicated (0–100 nm) for 2 h at 4 °C. 125I-VEGF bound to the plates was extracted and counted, and the average of triplicate determinations ± S.D. is presented. ANOVA was performed, and the conditions that showed a statistically significant increase in binding are indicated by *. B, Avastin was incubated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml)-coated plates in the presence and absence of VEGF (10 ng/ml) for 2 h at 4 °C, and then an ELISA protocol was used to detect bound Avastin. The average values of triplicate determinations ± S.D. are shown. Only conditions where VEGF and Avastin were incubated with biotin–heparin-coated plates produced a statistically significant signal above background. C, to understand whether heparin influences VEGF binding to Avastin, Avastin (0.5 nm) or <t>Fc-FGFR1</t> (0.5 nm)-coated protein A plates were incubated with 125I-VEGF (10 ng/ml) and the indicated concentration of heparin (0–100 μg/ml) for 2 h at 4 °C. The 125I-VEGF bound to the surface was extracted and measured. The average of triplicate values ± S.D. is presented. All concentrations of heparin tested produced a statistically significant increase in VEGF binding to Avastin.
    Fc Fgfr1 Chimeric Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fc fgfr1 chimeric protein/product/R&D Systems
    Average 86 stars, based on 8 article reviews
    fc fgfr1 chimeric protein - by Bioz Stars, 2026-02
    86/100 stars

    Images

    1) Product Images from "Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH"

    Article Title: Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH

    Journal: The Journal of Biological Chemistry

    doi: 10.1074/jbc.RA119.009194

    Avastin enhances VEGF binding to heparin and heparin binds VEGF–Avastin complexes and enhances VEGF binding to Avastin. A, streptavidin-coated 96-well microtiter plates were coated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml) and incubated with 125I-VEGF (10 ng/ml) alone or with Avastin at the concentrations indicated (0–100 nm) for 2 h at 4 °C. 125I-VEGF bound to the plates was extracted and counted, and the average of triplicate determinations ± S.D. is presented. ANOVA was performed, and the conditions that showed a statistically significant increase in binding are indicated by *. B, Avastin was incubated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml)-coated plates in the presence and absence of VEGF (10 ng/ml) for 2 h at 4 °C, and then an ELISA protocol was used to detect bound Avastin. The average values of triplicate determinations ± S.D. are shown. Only conditions where VEGF and Avastin were incubated with biotin–heparin-coated plates produced a statistically significant signal above background. C, to understand whether heparin influences VEGF binding to Avastin, Avastin (0.5 nm) or Fc-FGFR1 (0.5 nm)-coated protein A plates were incubated with 125I-VEGF (10 ng/ml) and the indicated concentration of heparin (0–100 μg/ml) for 2 h at 4 °C. The 125I-VEGF bound to the surface was extracted and measured. The average of triplicate values ± S.D. is presented. All concentrations of heparin tested produced a statistically significant increase in VEGF binding to Avastin.
    Figure Legend Snippet: Avastin enhances VEGF binding to heparin and heparin binds VEGF–Avastin complexes and enhances VEGF binding to Avastin. A, streptavidin-coated 96-well microtiter plates were coated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml) and incubated with 125I-VEGF (10 ng/ml) alone or with Avastin at the concentrations indicated (0–100 nm) for 2 h at 4 °C. 125I-VEGF bound to the plates was extracted and counted, and the average of triplicate determinations ± S.D. is presented. ANOVA was performed, and the conditions that showed a statistically significant increase in binding are indicated by *. B, Avastin was incubated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml)-coated plates in the presence and absence of VEGF (10 ng/ml) for 2 h at 4 °C, and then an ELISA protocol was used to detect bound Avastin. The average values of triplicate determinations ± S.D. are shown. Only conditions where VEGF and Avastin were incubated with biotin–heparin-coated plates produced a statistically significant signal above background. C, to understand whether heparin influences VEGF binding to Avastin, Avastin (0.5 nm) or Fc-FGFR1 (0.5 nm)-coated protein A plates were incubated with 125I-VEGF (10 ng/ml) and the indicated concentration of heparin (0–100 μg/ml) for 2 h at 4 °C. The 125I-VEGF bound to the surface was extracted and measured. The average of triplicate values ± S.D. is presented. All concentrations of heparin tested produced a statistically significant increase in VEGF binding to Avastin.

    Techniques Used: Binding Assay, Incubation, Enzyme-linked Immunosorbent Assay, Produced, Concentration Assay

    Avastin's capacity to inhibit VEGF binding to FN is reduced at acidic pH due to decreased Avastin–VEGF binding. A, 125I-VEGF (10 ng/ml) ± Avastin was incubated with FN-coated plates in binding buffer at the indicated pH values (5–8) for 2 h at 4 °C. After the incubation, 125I-VEGF bound to FN was extracted and counted. The average of triplicate values ± S.D. is shown. * indicates a statistically significant difference between VEGF binding in the presence and absence of Avastin; N.S. means not significant. B, values of 125I-VEGF bound in the presence and absence of Avastin were used calculate % VEGF binding inhibition at each pH using the equation: % VEGF binding inhibition = (VEGF bound (absence of Avastin) − (presence of Avastin)/VEGF bound in the absence of Avastin) × 100. C, 125I-VEGF (10 ng/ml) binding to Avastin (0.5 nm) bound to protein A plates was measured at various pH values after a 2-h incubation at 4 °C. 125I-VEGF association to Fc-FGFR1 (0.5 nm)-coated plates was also measured to control for nonspecific interactions. The average 125I-VEGF bound (fmol/well) ± S.D. of triplicate determinations is shown. Statistically significant reduction in VEGF binding compared with the value at pH 8 is noted (*).
    Figure Legend Snippet: Avastin's capacity to inhibit VEGF binding to FN is reduced at acidic pH due to decreased Avastin–VEGF binding. A, 125I-VEGF (10 ng/ml) ± Avastin was incubated with FN-coated plates in binding buffer at the indicated pH values (5–8) for 2 h at 4 °C. After the incubation, 125I-VEGF bound to FN was extracted and counted. The average of triplicate values ± S.D. is shown. * indicates a statistically significant difference between VEGF binding in the presence and absence of Avastin; N.S. means not significant. B, values of 125I-VEGF bound in the presence and absence of Avastin were used calculate % VEGF binding inhibition at each pH using the equation: % VEGF binding inhibition = (VEGF bound (absence of Avastin) − (presence of Avastin)/VEGF bound in the absence of Avastin) × 100. C, 125I-VEGF (10 ng/ml) binding to Avastin (0.5 nm) bound to protein A plates was measured at various pH values after a 2-h incubation at 4 °C. 125I-VEGF association to Fc-FGFR1 (0.5 nm)-coated plates was also measured to control for nonspecific interactions. The average 125I-VEGF bound (fmol/well) ± S.D. of triplicate determinations is shown. Statistically significant reduction in VEGF binding compared with the value at pH 8 is noted (*).

    Techniques Used: Binding Assay, Incubation, Inhibition



    Similar Products

    fc fgfr1 chimeric protein  (R&D Systems)
    86
    R&D Systems fc fgfr1 chimeric protein
    Avastin enhances VEGF binding to heparin and heparin binds VEGF–Avastin complexes and enhances VEGF binding to Avastin. A, streptavidin-coated 96-well microtiter plates were coated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml) and incubated with 125I-VEGF (10 ng/ml) alone or with Avastin at the concentrations indicated (0–100 nm) for 2 h at 4 °C. 125I-VEGF bound to the plates was extracted and counted, and the average of triplicate determinations ± S.D. is presented. ANOVA was performed, and the conditions that showed a statistically significant increase in binding are indicated by *. B, Avastin was incubated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml)-coated plates in the presence and absence of VEGF (10 ng/ml) for 2 h at 4 °C, and then an ELISA protocol was used to detect bound Avastin. The average values of triplicate determinations ± S.D. are shown. Only conditions where VEGF and Avastin were incubated with biotin–heparin-coated plates produced a statistically significant signal above background. C, to understand whether heparin influences VEGF binding to Avastin, Avastin (0.5 nm) or <t>Fc-FGFR1</t> (0.5 nm)-coated protein A plates were incubated with 125I-VEGF (10 ng/ml) and the indicated concentration of heparin (0–100 μg/ml) for 2 h at 4 °C. The 125I-VEGF bound to the surface was extracted and measured. The average of triplicate values ± S.D. is presented. All concentrations of heparin tested produced a statistically significant increase in VEGF binding to Avastin.
    Fc Fgfr1 Chimeric Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fc fgfr1 chimeric protein/product/R&D Systems
    Average 86 stars, based on 1 article reviews
    fc fgfr1 chimeric protein - by Bioz Stars, 2026-02
    86/100 stars
    		  Buy from Supplier
    fc-fgfr1 chimeric protein  (R&D Systems)
    90
    R&D Systems fc-fgfr1 chimeric protein
    Avastin enhances VEGF binding to heparin and heparin binds VEGF–Avastin complexes and enhances VEGF binding to Avastin. A, streptavidin-coated 96-well microtiter plates were coated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml) and incubated with 125I-VEGF (10 ng/ml) alone or with Avastin at the concentrations indicated (0–100 nm) for 2 h at 4 °C. 125I-VEGF bound to the plates was extracted and counted, and the average of triplicate determinations ± S.D. is presented. ANOVA was performed, and the conditions that showed a statistically significant increase in binding are indicated by *. B, Avastin was incubated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml)-coated plates in the presence and absence of VEGF (10 ng/ml) for 2 h at 4 °C, and then an ELISA protocol was used to detect bound Avastin. The average values of triplicate determinations ± S.D. are shown. Only conditions where VEGF and Avastin were incubated with biotin–heparin-coated plates produced a statistically significant signal above background. C, to understand whether heparin influences VEGF binding to Avastin, Avastin (0.5 nm) or <t>Fc-FGFR1</t> (0.5 nm)-coated protein A plates were incubated with 125I-VEGF (10 ng/ml) and the indicated concentration of heparin (0–100 μg/ml) for 2 h at 4 °C. The 125I-VEGF bound to the surface was extracted and measured. The average of triplicate values ± S.D. is presented. All concentrations of heparin tested produced a statistically significant increase in VEGF binding to Avastin.
    Fc Fgfr1 Chimeric Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fc-fgfr1 chimeric protein/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    fc-fgfr1 chimeric protein - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    recombinant chimeric fgfr1 β iiic  (R&D Systems)
    88
    R&D Systems recombinant chimeric fgfr1 β iiic
    Avastin enhances VEGF binding to heparin and heparin binds VEGF–Avastin complexes and enhances VEGF binding to Avastin. A, streptavidin-coated 96-well microtiter plates were coated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml) and incubated with 125I-VEGF (10 ng/ml) alone or with Avastin at the concentrations indicated (0–100 nm) for 2 h at 4 °C. 125I-VEGF bound to the plates was extracted and counted, and the average of triplicate determinations ± S.D. is presented. ANOVA was performed, and the conditions that showed a statistically significant increase in binding are indicated by *. B, Avastin was incubated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml)-coated plates in the presence and absence of VEGF (10 ng/ml) for 2 h at 4 °C, and then an ELISA protocol was used to detect bound Avastin. The average values of triplicate determinations ± S.D. are shown. Only conditions where VEGF and Avastin were incubated with biotin–heparin-coated plates produced a statistically significant signal above background. C, to understand whether heparin influences VEGF binding to Avastin, Avastin (0.5 nm) or <t>Fc-FGFR1</t> (0.5 nm)-coated protein A plates were incubated with 125I-VEGF (10 ng/ml) and the indicated concentration of heparin (0–100 μg/ml) for 2 h at 4 °C. The 125I-VEGF bound to the surface was extracted and measured. The average of triplicate values ± S.D. is presented. All concentrations of heparin tested produced a statistically significant increase in VEGF binding to Avastin.
    Recombinant Chimeric Fgfr1 β Iiic, supplied by R&D Systems, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant chimeric fgfr1 β iiic/product/R&D Systems
    Average 88 stars, based on 1 article reviews
    recombinant chimeric fgfr1 β iiic - by Bioz Stars, 2026-02
    88/100 stars
    		  Buy from Supplier
    chimeric protein fgfr1 (iiic/fc  (Enzo Biochem)
    90
    Enzo Biochem chimeric protein fgfr1 (iiic/fc
    Avastin enhances VEGF binding to heparin and heparin binds VEGF–Avastin complexes and enhances VEGF binding to Avastin. A, streptavidin-coated 96-well microtiter plates were coated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml) and incubated with 125I-VEGF (10 ng/ml) alone or with Avastin at the concentrations indicated (0–100 nm) for 2 h at 4 °C. 125I-VEGF bound to the plates was extracted and counted, and the average of triplicate determinations ± S.D. is presented. ANOVA was performed, and the conditions that showed a statistically significant increase in binding are indicated by *. B, Avastin was incubated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml)-coated plates in the presence and absence of VEGF (10 ng/ml) for 2 h at 4 °C, and then an ELISA protocol was used to detect bound Avastin. The average values of triplicate determinations ± S.D. are shown. Only conditions where VEGF and Avastin were incubated with biotin–heparin-coated plates produced a statistically significant signal above background. C, to understand whether heparin influences VEGF binding to Avastin, Avastin (0.5 nm) or <t>Fc-FGFR1</t> (0.5 nm)-coated protein A plates were incubated with 125I-VEGF (10 ng/ml) and the indicated concentration of heparin (0–100 μg/ml) for 2 h at 4 °C. The 125I-VEGF bound to the surface was extracted and measured. The average of triplicate values ± S.D. is presented. All concentrations of heparin tested produced a statistically significant increase in VEGF binding to Avastin.
    Chimeric Protein Fgfr1 (Iiic/Fc, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/chimeric protein fgfr1 (iiic/fc/product/Enzo Biochem
    Average 90 stars, based on 1 article reviews
    chimeric protein fgfr1 (iiic/fc - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Avastin enhances VEGF binding to heparin and heparin binds VEGF–Avastin complexes and enhances VEGF binding to Avastin. A, streptavidin-coated 96-well microtiter plates were coated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml) and incubated with 125I-VEGF (10 ng/ml) alone or with Avastin at the concentrations indicated (0–100 nm) for 2 h at 4 °C. 125I-VEGF bound to the plates was extracted and counted, and the average of triplicate determinations ± S.D. is presented. ANOVA was performed, and the conditions that showed a statistically significant increase in binding are indicated by *. B, Avastin was incubated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml)-coated plates in the presence and absence of VEGF (10 ng/ml) for 2 h at 4 °C, and then an ELISA protocol was used to detect bound Avastin. The average values of triplicate determinations ± S.D. are shown. Only conditions where VEGF and Avastin were incubated with biotin–heparin-coated plates produced a statistically significant signal above background. C, to understand whether heparin influences VEGF binding to Avastin, Avastin (0.5 nm) or Fc-FGFR1 (0.5 nm)-coated protein A plates were incubated with 125I-VEGF (10 ng/ml) and the indicated concentration of heparin (0–100 μg/ml) for 2 h at 4 °C. The 125I-VEGF bound to the surface was extracted and measured. The average of triplicate values ± S.D. is presented. All concentrations of heparin tested produced a statistically significant increase in VEGF binding to Avastin.

    Journal: The Journal of Biological Chemistry

    Article Title: Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH

    doi: 10.1074/jbc.RA119.009194

    Figure Lengend Snippet: Avastin enhances VEGF binding to heparin and heparin binds VEGF–Avastin complexes and enhances VEGF binding to Avastin. A, streptavidin-coated 96-well microtiter plates were coated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml) and incubated with 125I-VEGF (10 ng/ml) alone or with Avastin at the concentrations indicated (0–100 nm) for 2 h at 4 °C. 125I-VEGF bound to the plates was extracted and counted, and the average of triplicate determinations ± S.D. is presented. ANOVA was performed, and the conditions that showed a statistically significant increase in binding are indicated by *. B, Avastin was incubated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml)-coated plates in the presence and absence of VEGF (10 ng/ml) for 2 h at 4 °C, and then an ELISA protocol was used to detect bound Avastin. The average values of triplicate determinations ± S.D. are shown. Only conditions where VEGF and Avastin were incubated with biotin–heparin-coated plates produced a statistically significant signal above background. C, to understand whether heparin influences VEGF binding to Avastin, Avastin (0.5 nm) or Fc-FGFR1 (0.5 nm)-coated protein A plates were incubated with 125I-VEGF (10 ng/ml) and the indicated concentration of heparin (0–100 μg/ml) for 2 h at 4 °C. The 125I-VEGF bound to the surface was extracted and measured. The average of triplicate values ± S.D. is presented. All concentrations of heparin tested produced a statistically significant increase in VEGF binding to Avastin.

    Article Snippet: Recombinant human VEGF165 and Fc-FGFR1 chimeric protein were purchased from R&D Systems (Minneapolis, MN).

    Techniques: Binding Assay, Incubation, Enzyme-linked Immunosorbent Assay, Produced, Concentration Assay

    Avastin's capacity to inhibit VEGF binding to FN is reduced at acidic pH due to decreased Avastin–VEGF binding. A, 125I-VEGF (10 ng/ml) ± Avastin was incubated with FN-coated plates in binding buffer at the indicated pH values (5–8) for 2 h at 4 °C. After the incubation, 125I-VEGF bound to FN was extracted and counted. The average of triplicate values ± S.D. is shown. * indicates a statistically significant difference between VEGF binding in the presence and absence of Avastin; N.S. means not significant. B, values of 125I-VEGF bound in the presence and absence of Avastin were used calculate % VEGF binding inhibition at each pH using the equation: % VEGF binding inhibition = (VEGF bound (absence of Avastin) − (presence of Avastin)/VEGF bound in the absence of Avastin) × 100. C, 125I-VEGF (10 ng/ml) binding to Avastin (0.5 nm) bound to protein A plates was measured at various pH values after a 2-h incubation at 4 °C. 125I-VEGF association to Fc-FGFR1 (0.5 nm)-coated plates was also measured to control for nonspecific interactions. The average 125I-VEGF bound (fmol/well) ± S.D. of triplicate determinations is shown. Statistically significant reduction in VEGF binding compared with the value at pH 8 is noted (*).

    Journal: The Journal of Biological Chemistry

    Article Title: Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH

    doi: 10.1074/jbc.RA119.009194

    Figure Lengend Snippet: Avastin's capacity to inhibit VEGF binding to FN is reduced at acidic pH due to decreased Avastin–VEGF binding. A, 125I-VEGF (10 ng/ml) ± Avastin was incubated with FN-coated plates in binding buffer at the indicated pH values (5–8) for 2 h at 4 °C. After the incubation, 125I-VEGF bound to FN was extracted and counted. The average of triplicate values ± S.D. is shown. * indicates a statistically significant difference between VEGF binding in the presence and absence of Avastin; N.S. means not significant. B, values of 125I-VEGF bound in the presence and absence of Avastin were used calculate % VEGF binding inhibition at each pH using the equation: % VEGF binding inhibition = (VEGF bound (absence of Avastin) − (presence of Avastin)/VEGF bound in the absence of Avastin) × 100. C, 125I-VEGF (10 ng/ml) binding to Avastin (0.5 nm) bound to protein A plates was measured at various pH values after a 2-h incubation at 4 °C. 125I-VEGF association to Fc-FGFR1 (0.5 nm)-coated plates was also measured to control for nonspecific interactions. The average 125I-VEGF bound (fmol/well) ± S.D. of triplicate determinations is shown. Statistically significant reduction in VEGF binding compared with the value at pH 8 is noted (*).

    Article Snippet: Recombinant human VEGF165 and Fc-FGFR1 chimeric protein were purchased from R&D Systems (Minneapolis, MN).

    Techniques: Binding Assay, Incubation, Inhibition

    Avastin enhances VEGF binding to heparin and heparin binds VEGF–Avastin complexes and enhances VEGF binding to Avastin. A, streptavidin-coated 96-well microtiter plates were coated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml) and incubated with 125I-VEGF (10 ng/ml) alone or with Avastin at the concentrations indicated (0–100 nm) for 2 h at 4 °C. 125I-VEGF bound to the plates was extracted and counted, and the average of triplicate determinations ± S.D. is presented. ANOVA was performed, and the conditions that showed a statistically significant increase in binding are indicated by *. B, Avastin was incubated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml)-coated plates in the presence and absence of VEGF (10 ng/ml) for 2 h at 4 °C, and then an ELISA protocol was used to detect bound Avastin. The average values of triplicate determinations ± S.D. are shown. Only conditions where VEGF and Avastin were incubated with biotin–heparin-coated plates produced a statistically significant signal above background. C, to understand whether heparin influences VEGF binding to Avastin, Avastin (0.5 nm) or Fc-FGFR1 (0.5 nm)-coated protein A plates were incubated with 125I-VEGF (10 ng/ml) and the indicated concentration of heparin (0–100 μg/ml) for 2 h at 4 °C. The 125I-VEGF bound to the surface was extracted and measured. The average of triplicate values ± S.D. is presented. All concentrations of heparin tested produced a statistically significant increase in VEGF binding to Avastin.

    Journal: The Journal of Biological Chemistry

    Article Title: Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH

    doi: 10.1074/jbc.RA119.009194

    Figure Lengend Snippet: Avastin enhances VEGF binding to heparin and heparin binds VEGF–Avastin complexes and enhances VEGF binding to Avastin. A, streptavidin-coated 96-well microtiter plates were coated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml) and incubated with 125I-VEGF (10 ng/ml) alone or with Avastin at the concentrations indicated (0–100 nm) for 2 h at 4 °C. 125I-VEGF bound to the plates was extracted and counted, and the average of triplicate determinations ± S.D. is presented. ANOVA was performed, and the conditions that showed a statistically significant increase in binding are indicated by *. B, Avastin was incubated with biotin (1 μg/ml) or biotin–heparin (5 μg/ml)-coated plates in the presence and absence of VEGF (10 ng/ml) for 2 h at 4 °C, and then an ELISA protocol was used to detect bound Avastin. The average values of triplicate determinations ± S.D. are shown. Only conditions where VEGF and Avastin were incubated with biotin–heparin-coated plates produced a statistically significant signal above background. C, to understand whether heparin influences VEGF binding to Avastin, Avastin (0.5 nm) or Fc-FGFR1 (0.5 nm)-coated protein A plates were incubated with 125I-VEGF (10 ng/ml) and the indicated concentration of heparin (0–100 μg/ml) for 2 h at 4 °C. The 125I-VEGF bound to the surface was extracted and measured. The average of triplicate values ± S.D. is presented. All concentrations of heparin tested produced a statistically significant increase in VEGF binding to Avastin.

    Article Snippet: Recombinant human VEGF165 and Fc-FGFR1 chimeric protein were purchased from R&D Systems (Minneapolis, MN).

    Techniques: Binding Assay, Incubation, Enzyme-linked Immunosorbent Assay, Produced, Concentration Assay

    Avastin's capacity to inhibit VEGF binding to FN is reduced at acidic pH due to decreased Avastin–VEGF binding. A, 125I-VEGF (10 ng/ml) ± Avastin was incubated with FN-coated plates in binding buffer at the indicated pH values (5–8) for 2 h at 4 °C. After the incubation, 125I-VEGF bound to FN was extracted and counted. The average of triplicate values ± S.D. is shown. * indicates a statistically significant difference between VEGF binding in the presence and absence of Avastin; N.S. means not significant. B, values of 125I-VEGF bound in the presence and absence of Avastin were used calculate % VEGF binding inhibition at each pH using the equation: % VEGF binding inhibition = (VEGF bound (absence of Avastin) − (presence of Avastin)/VEGF bound in the absence of Avastin) × 100. C, 125I-VEGF (10 ng/ml) binding to Avastin (0.5 nm) bound to protein A plates was measured at various pH values after a 2-h incubation at 4 °C. 125I-VEGF association to Fc-FGFR1 (0.5 nm)-coated plates was also measured to control for nonspecific interactions. The average 125I-VEGF bound (fmol/well) ± S.D. of triplicate determinations is shown. Statistically significant reduction in VEGF binding compared with the value at pH 8 is noted (*).

    Journal: The Journal of Biological Chemistry

    Article Title: Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH

    doi: 10.1074/jbc.RA119.009194

    Figure Lengend Snippet: Avastin's capacity to inhibit VEGF binding to FN is reduced at acidic pH due to decreased Avastin–VEGF binding. A, 125I-VEGF (10 ng/ml) ± Avastin was incubated with FN-coated plates in binding buffer at the indicated pH values (5–8) for 2 h at 4 °C. After the incubation, 125I-VEGF bound to FN was extracted and counted. The average of triplicate values ± S.D. is shown. * indicates a statistically significant difference between VEGF binding in the presence and absence of Avastin; N.S. means not significant. B, values of 125I-VEGF bound in the presence and absence of Avastin were used calculate % VEGF binding inhibition at each pH using the equation: % VEGF binding inhibition = (VEGF bound (absence of Avastin) − (presence of Avastin)/VEGF bound in the absence of Avastin) × 100. C, 125I-VEGF (10 ng/ml) binding to Avastin (0.5 nm) bound to protein A plates was measured at various pH values after a 2-h incubation at 4 °C. 125I-VEGF association to Fc-FGFR1 (0.5 nm)-coated plates was also measured to control for nonspecific interactions. The average 125I-VEGF bound (fmol/well) ± S.D. of triplicate determinations is shown. Statistically significant reduction in VEGF binding compared with the value at pH 8 is noted (*).

    Article Snippet: Recombinant human VEGF165 and Fc-FGFR1 chimeric protein were purchased from R&D Systems (Minneapolis, MN).

    Techniques: Binding Assay, Incubation, Inhibition